Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of KOD is 31 and suggests 33% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell